Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Kanaph Therapeutics logo — We are the leader of next generation immuno-oncology and aut...

Kanaph Therapeutics

We are the leader of next generation immuno-oncology and autoimmune diseases.

Founded 2019 Korea South Korea South 16 employees Series B Total: $27.00M Biotechnology, Pharmaceutical

General Information

Company Name Kanaph Therapeutics
Founded Year 2019
Location Korea South Korea South
Employees 16
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Kanaph Therapeutics. To contact Kanaph Therapeutics, visit kanaphtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kanaph Therapeutics compare?

A PDF of Kanaph Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kanaph Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kanaph Therapeutics

Kanaph Therapeutics is a leading player in next-generation immuno-oncology and autoimmune disease therapeutics. Established in 2019 in South Korea, the company focuses on drug discovery and pre-clinical stage biotech with a dual-track strategy for large and small molecule development. Their goal is to create first-in-class and best-in-class therapeutics for immuno-oncology, targeted therapy, and autoimmune diseases, particularly in ophthalmology. The company's oncology pipeline boasts bi-specific antibodies and small molecules that demonstrate significantly improved immuno-stimulatory activity within the tumor micro-environment to effectively eradicate tumors. Simultaneously, their autoimmune disease pipeline includes bispecific Fc-fusions designed to inhibit the alternative complement pathway, angiogenesis, and downstream complement activation. Kanaph recently secured a $21.00M Series B investment on October 12, 2020. The investment was led by Kolon Investment, Timepolio Asset Management, and Green Cross. With its innovative approach to tackling critical medical challenges and significant investment backing, Kanaph Therapeutics is poised to make a substantial impact within the biotechnology and pharmaceutical industries.

Business keywords: immuno-oncology, autoimmune diseases, drug discovery, pre-clinical stage biotech, bi-specific antibodies, small molecules, immuno-stimulatory activity, tumor micro-environment, autoimmune disease pipeline, complement pathway, angiogenesis, immunotherapy, therapeutics development, Korea-based biotech, immune system modulation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $21.00M 3
Kolon Investment
Kolon Investment, Timepolio Asset Management +1
12 Oct 2020
Series A $6.00M 2
Meritz Securities
Meritz Securities, Timepolio Asset Management
22 Oct 2019

Kanaph Therapeutics Alternatives & Competitors

View All Alternatives
Kanaph Therapeutics vs
OSE Immunotherapeutics
OSE Immunotherapeutics France

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients

Grant
76 employees
Biotechnology, Medical Devices
Compare Kanaph Therapeutics vs OSE Immunotherapeutics
Kanaph Therapeutics vs
Macomics
Macomics United Kingdom

Macrophage Biology Revealed:Developing breakthrough approaches to macrophage activity to change the...

Series A
24 employees
Biotechnology, Health and Wellness
Kanaph Therapeutics vs
Nirogy Therapeutics
Nirogy Therapeutics

Pioneering innovative small molecules to disrupt metabolic and immune pathways, advancing therapeuti...

Series A
2-10 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Kanaph Therapeutics

We are the leader of next generation immuno-oncology and autoimmune diseases.
Kanaph Therapeutics was founded in 2019.
Kanaph Therapeutics is headquartered in Korea South.
Kanaph Therapeutics operates in Biotechnology and Pharmaceutical. Its work centres on immuno-oncology, autoimmune diseases, drug discovery and pre-clinical stage biotech.
Kanaph Therapeutics has approximately 16 employees.
Kanaph Therapeutics has completed 2 funding rounds, raising a total of $27.00M. The latest funding stage is Series B.
Top alternatives and competitors to Kanaph Therapeutics include OSE Immunotherapeutics, Macomics, Nirogy Therapeutics, Biond Biologics Ltd, Innate Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kanaph Therapeutics and OSE Immunotherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kanaph Therapeutics, https://bouncewatch.com/company/kanaph-therapeutics, updated 9 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout